Viking Global Investors LP Vertex Pharmaceuticals Inc Transaction History

Viking Global Investors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2016 May 16, 2016	SELL	N/A	-1,421,673 Closed	0 $0
Q4 2015 Feb 16, 2016	BUY	N/A	77,209 Added 5.74%	1,421,673 $179 Million
Q3 2015 Nov 16, 2015	SELL	N/A	-460,722 Reduced 25.52%	1,344,464 $140 Million
Q2 2015 Aug 14, 2015	BUY	N/A	35,036 Added 1.98%	1,805,186 $223 Million
Q1 2015 May 15, 2015	BUY	N/A	1,005,950 Added 131.63%	1,770,150 $209 Million
Q4 2014 Feb 17, 2015	BUY	N/A	764,200	764,200 $90.8 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.